Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SEPN |
---|---|---|
09:32 ET | 409 | 23.095 |
09:33 ET | 4310 | 22.82 |
09:35 ET | 400 | 22.7 |
09:37 ET | 400 | 22.68 |
09:39 ET | 200 | 23.225 |
09:44 ET | 200 | 23.165 |
09:46 ET | 100 | 23.09 |
09:55 ET | 100 | 22.7723 |
10:09 ET | 100 | 22.7 |
10:13 ET | 100 | 22.68 |
10:15 ET | 200 | 22.68 |
10:20 ET | 500 | 23.06 |
10:24 ET | 716 | 22.71 |
10:26 ET | 300 | 22.705 |
10:33 ET | 329 | 22.635 |
10:36 ET | 100 | 22.62 |
10:38 ET | 100 | 22.62 |
10:40 ET | 200 | 22.61 |
10:44 ET | 400 | 22.88 |
10:45 ET | 1743 | 23.12 |
10:47 ET | 476 | 23 |
10:49 ET | 500 | 22.96 |
10:54 ET | 100 | 22.985 |
10:56 ET | 100 | 23.035 |
11:02 ET | 100 | 23.05 |
11:03 ET | 400 | 23 |
11:07 ET | 200 | 22.995 |
11:12 ET | 100 | 23 |
11:14 ET | 555 | 23 |
11:16 ET | 100 | 23 |
11:23 ET | 312 | 23 |
11:27 ET | 200 | 22.965 |
11:36 ET | 130 | 22.925 |
11:38 ET | 100 | 22.71 |
11:39 ET | 300 | 22.705 |
11:50 ET | 100 | 22.605 |
11:52 ET | 300 | 22.51 |
12:10 ET | 100 | 22.505 |
12:19 ET | 140 | 22.485 |
12:26 ET | 100 | 22.485 |
12:32 ET | 100 | 22.47 |
12:42 ET | 3220 | 22.66 |
12:44 ET | 100 | 22.66 |
12:46 ET | 1700 | 22.78 |
12:48 ET | 2561 | 22.86 |
12:50 ET | 200 | 22.945 |
12:51 ET | 3468 | 22.885 |
12:53 ET | 300 | 22.49 |
12:57 ET | 100 | 22.45 |
01:00 ET | 800 | 22.1 |
01:02 ET | 100 | 22.08 |
01:04 ET | 200 | 21.96 |
01:06 ET | 200 | 22.115 |
01:08 ET | 3251 | 21.77 |
01:09 ET | 100 | 21.97 |
01:13 ET | 200 | 21.97 |
01:15 ET | 100 | 22.21 |
01:18 ET | 200 | 21.97 |
01:22 ET | 200 | 21.97 |
01:24 ET | 200 | 21.97 |
01:26 ET | 700 | 21.975 |
01:31 ET | 1000 | 22.22 |
01:33 ET | 500 | 22.44 |
01:36 ET | 506 | 22.22 |
01:38 ET | 100 | 22.43 |
01:40 ET | 600 | 22.29 |
01:44 ET | 100 | 22.5 |
01:45 ET | 300 | 22.405 |
01:49 ET | 200 | 22.405 |
01:51 ET | 100 | 22.345 |
01:56 ET | 400 | 22.32 |
01:58 ET | 100 | 22.32 |
02:09 ET | 2338 | 22.49 |
02:12 ET | 400 | 22.545 |
02:14 ET | 100 | 22.54 |
02:16 ET | 100 | 22.545 |
02:20 ET | 100 | 22.545 |
02:21 ET | 8892 | 22.49 |
02:25 ET | 1000 | 22.605 |
02:27 ET | 3430 | 22.74 |
02:30 ET | 100 | 22.84 |
02:32 ET | 400 | 22.84 |
02:34 ET | 100 | 22.78 |
02:36 ET | 300 | 22.715 |
02:38 ET | 200 | 22.59 |
02:41 ET | 200 | 22.63 |
02:45 ET | 330 | 22.51 |
02:48 ET | 100 | 22.53 |
02:50 ET | 100 | 22.455 |
02:52 ET | 350 | 22.32 |
02:54 ET | 100 | 22.33 |
02:56 ET | 445 | 22.35 |
02:59 ET | 100 | 22.33 |
03:01 ET | 100 | 22.49 |
03:03 ET | 300 | 22.39 |
03:06 ET | 1600 | 22.39 |
03:08 ET | 200 | 22.39 |
03:10 ET | 3688 | 22.345 |
03:12 ET | 100 | 22.325 |
03:14 ET | 100 | 22.32 |
03:15 ET | 400 | 22.26 |
03:17 ET | 200 | 22.08 |
03:19 ET | 900 | 22.04 |
03:21 ET | 2600 | 21.9 |
03:24 ET | 300 | 21.91 |
03:26 ET | 100 | 22.03 |
03:28 ET | 200 | 22.03 |
03:30 ET | 400 | 21.87 |
03:32 ET | 716 | 22.035 |
03:33 ET | 300 | 22.03 |
03:35 ET | 400 | 22.025 |
03:37 ET | 200 | 21.975 |
03:39 ET | 750 | 21.935 |
03:42 ET | 300 | 21.84 |
03:44 ET | 314 | 21.945 |
03:46 ET | 1714 | 21.89 |
03:48 ET | 3688 | 21.79 |
03:50 ET | 4508 | 22.11 |
03:51 ET | 3600 | 22.16 |
03:53 ET | 2150 | 22.08 |
03:55 ET | 5196 | 21.74 |
03:57 ET | 3053 | 21.825 |
04:00 ET | 21297 | 21.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Septerna Inc | 915.2M | -87,160.0x | --- |
Nuvation Bio Inc | 908.7M | -1.2x | --- |
Arrivent Biopharma Inc | 893.0M | -10.1x | --- |
LENZ Therapeutics Inc | 943.8M | -4.8x | --- |
Bicara Therapeutics Inc | 870.1M | 0.0x | --- |
Upstream Bio Inc | 954.0M | 0.0x | --- |
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. It is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $915.2M |
---|---|
Revenue (TTM) | $840.00 |
Shares Outstanding | 42.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.00 |
Book Value | $0.00 |
P/E Ratio | -87,160.0x |
Price/Sales (TTM) | 1,089,573.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,342.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.